The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry

• Published in: The open cardiovascular medicine journal 2017-01, Vol.11 (1), p.66-75
• Main Authors: Alallaf, Faisal, H Nazar, Fatima Amanullah, Alnefaie, Majed, Almaymuni, Adel, Rashidi, Omran Mohammed, Alhabib, Khalid, Alnouri, Fahad, Alama, Mohamed-Nabil, Athar, Mohammad, Awan, Zuhier
• Format: Article
• Language: English
• ISSN: 1874-1924; 1874-1924
• DOI: 10.2174/1874192401711010066

Familial hypercholesterolemia (FH) is a life-threatening inherited condition. Untreated patients have the risk to develop raised plasma levels of cholesterol, atherosclerosis and cardiovascular disease (CVD). If diagnosed and treated early in life, the pathological consequences due to atherosclerosis could be avoided and patients with FH can have an anticipated normal life. Mounting evidence suggests that FH is underdiagnosed and undertreated in all populations. The underlying molecular basis of FH is the presence of mutations in one or more genes in the low-density lipoprotein receptor ( ), apolipoprotein B ( ) or proprotein convertase subtilisin/kexin 9 ( ). However, their prevalence is largely unknown in Saudi Arabia but given the high rates of consanguinity, the prevalence appears to be higher. Furthermore, the high prevalence of obesity and diabetes mellitus in Saudi Arabia increases the vascular disease burden in FH cases by adding additional CVD risk factors. This article explores the spectrum of FH-causing mutations in the highly consanguineous Saudi community, the need for establishing the Saudi FH registry, the challenges in creating gene databases, and cascade screening. The establishment of FH registry and genetic testing should raise awareness not only among healthcare professionals, but the general population as well. It also helps to provide the best treatment regimen in a cost effective manner to this under-recognised population of FH patients.